GF Fund Management CO. LTD. Buys 3,101 Shares of Johnson & Johnson (NYSE:JNJ)

GF Fund Management CO. LTD. boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,449 shares of the company's stock after acquiring an additional 3,101 shares during the quarter. GF Fund Management CO. LTD.'s holdings in Johnson & Johnson were worth $10,522,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. OneDigital Investment Advisors LLC lifted its stake in Johnson & Johnson by 1.1% during the first quarter. OneDigital Investment Advisors LLC now owns 87,424 shares of the company's stock valued at $14,498,000 after purchasing an additional 916 shares during the last quarter. 44 Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.4% during the 1st quarter. 44 Wealth Management LLC now owns 18,269 shares of the company's stock valued at $3,030,000 after acquiring an additional 260 shares during the last quarter. Avantax Planning Partners Inc. grew its holdings in shares of Johnson & Johnson by 4.0% in the 1st quarter. Avantax Planning Partners Inc. now owns 44,955 shares of the company's stock worth $7,455,000 after acquiring an additional 1,717 shares during the last quarter. Silver Oak Securities Incorporated lifted its holdings in shares of Johnson & Johnson by 13.8% during the first quarter. Silver Oak Securities Incorporated now owns 8,637 shares of the company's stock valued at $1,414,000 after purchasing an additional 1,045 shares during the last quarter. Finally, Calamos Wealth Management LLC boosted its position in shares of Johnson & Johnson by 15.3% in the 1st quarter. Calamos Wealth Management LLC now owns 116,394 shares of the company's stock valued at $19,303,000 after purchasing an additional 15,447 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on JNJ shares. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.49 during midday trading on Tuesday, reaching $155.76. 6,432,336 shares of the company traded hands, compared to its average volume of 8,057,313. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market cap of $374.77 billion, a PE ratio of 17.33, a PEG ratio of 2.35 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock's 50-day simple moving average is $153.67 and its 200-day simple moving average is $154.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.